By Chris Quigley
Upjohn manufactures older brands like Lipitor and Viagra, while Mylan ([[MYL]]) is best know for making generic drugs and for its EpiPen. Pfizer ([[PFE]]) shareholders will end up owning 57% of the combined entity. After the spinoff, Upjohn will make a $12 billion payment to Pfizer.
Analysts offered mixed views on the go-forward PFE, with some saying it was a smart choice to further focus on growth drivers, while Mylan as a standalone company was very inexpensively valued, and others were concerned about the lost revenue, cash flow and profits.
No doubt,